Jiafu F. Ji

Key Laboratory Of Carcinogenesis And Translational Research
Beijing, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 88 publications

Perioperative serplulimab with neoadjuvant chemotherapy versus perioperative chemotherapy in PD-L1-positive gastric cancer (ASTRUM-006): a randomised, double-blind, multicentre, phase 3 study.

Perioperative serplulimab with neoadjuvant chemotherapy versus perioperative chemotherapy in PD-L1-positive gastric cancer (ASTRUM-006): a randomised, double-blind, multicentre, phase 3 study.

Journal: Lancet (London, England)

Published: April 08, 2026

Tumor microenvironment dynamics in gastric cancer pathogenesis and therapeutic resistance.

Tumor microenvironment dynamics in gastric cancer pathogenesis and therapeutic resistance.

Journal: Molecular cancer

Published: October 14, 2025

Author Correction: First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial.

Author Correction: First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial.

Journal: Nature medicine

Published: March 27, 2025

A spatially resolved atlas of gastric cancer characterises a lymphocyte-aggregated region.

A spatially resolved atlas of gastric cancer characterises a lymphocyte-aggregated region.

Journal: Nature communications

Published: January 18, 2025

First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial.

First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial.

Journal: Nature medicine

Published: September 29, 2024

Generating research hypotheses to overcome key challenges in the early diagnosis of colorectal cancer - Future application of AI.

Generating research hypotheses to overcome key challenges in the early diagnosis of colorectal cancer - Future application of AI.

Journal: Cancer letters

Published: September 23, 2024

Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): final report of a randomised, open-label, phase 3 trial.

Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): final report of a randomised, open-label, phase 3 trial.

Journal: The Lancet. Oncology

Published: August 22, 2024

Current status and challenges of model-informed drug discovery and development in China.

Current status and challenges of model-informed drug discovery and development in China.

Journal: Advanced drug delivery reviews

Published: May 28, 2024

The deubiquitinase USP15 drives malignant progression of gastric cancer through glucose metabolism remodeling.

The deubiquitinase USP15 drives malignant progression of gastric cancer through glucose metabolism remodeling.

Journal: Journal of experimental & clinical cancer research : CR

Published: May 04, 2024

Tumor-infiltrating immune cell profiles and changes associate with additional trastuzumab in preoperative chemotherapy for patients with HER2-positive gastric cancer.

Tumor-infiltrating immune cell profiles and changes associate with additional trastuzumab in preoperative chemotherapy for patients with HER2-positive gastric cancer.

Journal: British journal of cancer

Published: April 16, 2024

NIR-II light in clinical oncology: opportunities and challenges.

NIR-II light in clinical oncology: opportunities and challenges.

Journal: Nature reviews. Clinical oncology

Published: April 04, 2024

Exploring the potential of extrachromosomal DNA as a novel oncogenic driver.

Exploring the potential of extrachromosomal DNA as a novel oncogenic driver.

Journal: Science China. Life sciences

Published: March 12, 2024

Showing 1-12 of 88

Last Updated: 09/26/2026